Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1614 1628
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18615080 | COMPOSITIONS AND METHODS FOR MUSCLE REGENERATION USING PROSTAGLANDIN E2 | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | Non-Final OA | AbbVie Inc. |
| 18040858 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-L1) EXPRESSION | Non-Final OA | The Johns Hopkins University |
| 17735753 | COMPOSITION COMPRISING ALKYLCELLULOSE, INCOMPATIBLE HYDROCARBON AND SILICONE OILS AND METHOD EMPLOYING IT | Final Rejection | L'OREAL |
| 18708916 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 17596779 | COMPOSITIONS AND METHODS USING THYMOL AND/OR CARVACROL FOR INDUCTION OF AUTOPHAGY | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18141086 | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION AS OPHTHALMIC DROP TO PATIENT REQUIRING OPTIC NERVE PROTECTION | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | Non-Final OA | Janssen Pharmaceutica NV |
| 18612306 | Methods of Treating Neurologic Disorders | Non-Final OA | GEORGETOWN UNIVERSITY |
| 17642732 | COSMETIC COMPOSITION WITH ENHANCED COLOR STABILITY | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 18759232 | Treatment of Pneumonia | Non-Final OA | COMBIOXIN SA |
| 18249829 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17773775 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18027144 | N-((1-BENZYLPIPERIDIN-3-YL)METHYL)-N-(2-METHOXYETHYL)NAPHTHALENE-2-SULFONAMIDE FOR THE TREATMENT OF CANINE COGNITIVE DYSFUNCTION AND OTHER FORMS OF DEMENTIA IN DOGS | Final Rejection | UNIVERZA V LJUBLJANI |
| 17621002 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | Final Rejection | Research Triangle Institute |
| 18577129 | NANOPARTICLES FOR CANCER TREATMENT | Non-Final OA | Immix Biopharma, Inc. |
| 18386828 | Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders | Non-Final OA | Corcept Therapeutics Incorporated |
| 18456718 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Final Rejection | Arvinas Operations, Inc. |
| 17929511 | METHODS AND SYSTEMS FOR NITRIC OXIDE THERAPY FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS | Non-Final OA | KNOW Bio, LLC |
| 18257166 | MACROCYCLES AND THEIR USE | Non-Final OA | BLOSSOMHILL THERAPEUTICS, INC. |
| 18004829 | MACROCYCLES AND THEIR USE | Non-Final OA | BLOSSOMHILL THERAPEUTICS, INC. |
| 18265933 | COMBINATION THERAPY COMPRISING UNCARIA FOR TREATING ANXIETY AND DEPRESSION | Non-Final OA | The Open University |
| 17717691 | Increasing Drug Bioavailability In Naltrexone Therapy | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 17343326 | Increasing Drug Bioavailability In Naltrexone Therapy | Final Rejection | Nalpropion Pharmaceuticals LLC |
| 17829538 | COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF | Non-Final OA | GIVAUDAN S.A. |
| 17798421 | METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCER CELLS | Final Rejection | BioTissue Holdings Inc. |
| 18108443 | DRESSING, A KIT COMPRISING A DRESSING AND A METHOD OF PREPARING A DRESSING | Non-Final OA | Chemence Medical Inc. |
| 18040959 | OPTIMIZED SURGERY PROTOCOL AND KITS | Non-Final OA | Steadman Philippon Research Institute |
| 18017997 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | Non-Final OA | UBIX THERAPEUTICS, INC. |
| 17757857 | SOLID PREPARATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | Sinotherapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy